Status:
UNKNOWN
Von Willebrand Factor and Protein C Ratio in Graft Function After Liver Transplant
Lead Sponsor:
Asan Medical Center
Conditions:
Liver Transplant; Complications
Eligibility:
All Genders
18+ years
Brief Summary
In liver cirrhosis (LC),the activity of von Willebrand factor (vWF)-cleaving enzyme ADAMTS13 is reduced in LC patients and consequent progression of liver injury. Remarkably, it has been reported that...
Eligibility Criteria
Inclusion
- patients who underwent LT
Exclusion
- deceased-donor liver transplant, and insufficient data, ABO-incompatible LT
Key Trial Info
Start Date :
January 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2020
Estimated Enrollment :
1199 Patients enrolled
Trial Details
Trial ID
NCT04324255
Start Date
January 1 2014
End Date
April 30 2020
Last Update
March 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical center
Seoul, South Korea, 05505